Moreover, oxaliplatin selectively induced the upregulation of NKG2DL expression on GC cell HGC-27 and N87, thus activating the NKG2D/NKG2DL receptor-ligand pathway, and enhancing the tumor cell-killing effects of NK cells in vitro. The gene discussed is KLRK1; the disease is gastric cancer.